Completed PHASE4 INTERVENTIONAL 2-arm NCT01471821

Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression (OLE)

Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy Instead of a Triple Therapy That Includes Lopinavir/Ritonavir and Lamivudine or Emtricitabine in HIV Patients With Viral Suppression: Controlled Clinical Trial, Open Label, Randomized, of 48 Weeks of Follow-up

Sponsor: Juan A. Arnaiz

Conditions HIV Infection

Interventions antiretroviral treatment

Updated 5 times since 2017 Last updated: Jul 28, 2014 Started: Oct 31, 2011 Primary completion: Apr 30, 2014 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates HIV Infection and is currently completed. Juan A. Arnaiz leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Juan A. Arnaiz

Data source: Hospital Clinic of Barcelona

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Barcelona, Spain
• Madrid, Spain